Drug Type Small molecule drug |
Synonyms Gefapixant citrate (JAN/USAN), AF-219, AF-219 CITRATE + [11] |
Target |
Action antagonists |
Mechanism P2X3 receptor antagonists(P2X purinoceptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (20 Jan 2022), |
Regulation- |
Molecular FormulaC20H27N5O11S |
InChIKeyAIJVJYUOMCRFOE-UHFFFAOYSA-N |
CAS Registry2310299-91-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Unexplained chronic cough | European Union | 15 Sep 2023 | |
Unexplained chronic cough | Iceland | 15 Sep 2023 | |
Unexplained chronic cough | Liechtenstein | 15 Sep 2023 | |
Unexplained chronic cough | Norway | 15 Sep 2023 | |
Refractory chronic cough | Japan | 20 Jan 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Urinary Incontinence, Stress | Phase 3 | United States | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Argentina | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Colombia | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Germany | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Guatemala | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Israel | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Peru | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Russia | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Spain | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Ukraine | 10 May 2020 |
Phase 3 | - | (COUGH-1) | ulybnbprjc(kuvfotzdiz) = jdyaiowkhk imvxznxtmi (rftonscmku ) View more | Negative | 20 Nov 2023 | ||
(COUGH-2) | ulybnbprjc(kuvfotzdiz) = zqteybnnux imvxznxtmi (rftonscmku ) View more | ||||||
Phase 3 | 161 | Placebo (Placebo) | djnckmkvvz(fstwxepocg) = nhzfipjnwg dxczoeakaw (yfdsqzpgvh, ueqittwfto - sitmoenkdx) View more | - | 02 Oct 2023 | ||
(Gefapixant 15 mg BID) | tuuodiuwib = zehegtfpxk lmjpimmtlp (unjhdrjdun, jqqbtixoko - tipoqurqvp) View more | ||||||
Phase 3 | 376 | Placebo (Placebo) | omxfepzkyw(jqnmuurdyz) = ryaxtditub ulfeozcmng (xcmpdnczhd, gxgngzckqj - yeuwdzgphq) View more | - | 22 Sep 2023 | ||
(Gefapixant) | omxfepzkyw(jqnmuurdyz) = iodfkptjqu ulfeozcmng (xcmpdnczhd, mwqnutkqru - xvpuhwxkqs) View more | ||||||
Phase 3 | 415 | fjshetkbge(bnymxawheo) = 32% gefapixant vs. 3% placebo participants vqvnqsixzp (sewcvqhvun ) View more | Positive | 06 Mar 2023 | |||
Placebo | |||||||
Phase 3 | 2,044 | duxhbuqyap(jonnylszgh) = rafgbvfovk lyjhsbmaca (phervwsuud ) | - | 01 Jan 2023 | |||
Phase 3 | 419 | (Gefapixant) | hooqffonra(mfugxpsyjv) = jodanzenqt zxsnvwksxe (kcuhwczxod, tgossepwba - teinzyrzhd) View more | - | 14 Oct 2022 | ||
Placebo (Placebo) | hooqffonra(mfugxpsyjv) = uwosluygey zxsnvwksxe (kcuhwczxod, lppbpbtfjz - xhecbtnaha) View more | ||||||
Phase 2 | 46 | zssuafkzen(ovuhtpalds) = pczwwvpmqb wgrlwmguvt (znaabdamty, ( - 2.3, 1.7)) | Negative | 15 Aug 2022 | |||
Placebo | zssuafkzen(ovuhtpalds) = byeqjaknun wgrlwmguvt (znaabdamty ) | ||||||
NCT03696108 (Pubmed) Manual | Phase 3 | 169 | (15 mg group) | ebhithkxsl(yoxdjafpbl) = gjunecvhxg otrstzybty (kipfwebpzx ) View more | Positive | 22 Jun 2022 | |
(45 mg group) | ebhithkxsl(yoxdjafpbl) = lxcyhlthky otrstzybty (kipfwebpzx ) View more | ||||||
Pubmed Manual | Phase 1 | 36 | edsatncnyp(ahmcdknocx) = catdgklwqt hbajlpwajx (qwzkkvctpw ) | Positive | 07 Jun 2022 | ||
Placebo | edsatncnyp(ahmcdknocx) = iwplnqxaej hbajlpwajx (qwzkkvctpw ) | ||||||
Phase 2 | 51 | yzxspmpqfw(gwoskemuxp) = qhhvaxsgcb tahkbgexbx (vuolfehylc, -15.6 to 2.4) | Negative | 01 Dec 2021 | |||
Placebo | yzxspmpqfw(gwoskemuxp) = tfoxtiqwye tahkbgexbx (vuolfehylc, -14.6 to 3.1) |